Journal of Virology · 1995 · 78 citations · 14 references
Life SciencesImmunologyInfectious DiseasesImmunizationImmunology Of Infectious DiseasesVaccinologyAntiviral ImmunityCell-mediated ImmunityCellular Immunity In InfectionImmune Response To VaccinationVaccinationViral VaccinesCd4 Positive T CellsCd4 T-cell DepletionCd8 Positive T CellsCellular Immune Response To VirusesDelayed Hypersensitivity ReactionsHerpes Simplex Virus VaccinesMechanisms Of Vaccine-induced ProtectionT-cell Mediated Immunity
This study was designed to evaluate the efficacy and mechanisms of protection mediated by recombinant vaccinia viruses encoding immediate-early (IE) proteins of herpes simplex virus type 2 (HSV-2). Three mouse strains were immunized against the IE proteins ICP27, ICP0, and ICP4, and mice were challenged intracutaneously in the zosteriform model with HSV-2 strain MS. Protection was observed only following immunization with the ICP27 construct and then only in the BALB/c mouse strain. Protection in BALB/c mice was ablated by CD4+ T-cell suppression but remained intact in animals depleted of CD8+ T cells. Moreover, protection could be afforded to SCID nude recipients with CD4+ but not CD8+ T cells from ICP27-immunized mice. Only BALB/c mice developed a delayed-type hypersensitivity reaction to HSV-2, and in vitro measurements of humoral and cell-mediated immunity revealed response patterns to ICP27 and HSV that differed between protected BALB/c and unprotected mouse strains. Accordingly, BALB/c responses showed antigen-induced cytokine profiles dominated by type 1 cytokines, whereas C57BL/6 and C3H/HeN mice generated cytokine responses mainly of the type 2 variety. Our results may indicate that protection against zosterification is mainly mediated by CD4+ T cells that express a type 1 cytokine profile and that protective vaccines against HSV which effectively induce such T-cell responses should be chosen.
14